Emerging intralesional therapies for BCC

Surgery is the first-line treatment for patients with basal cell carcinoma (BCC). However, intralesional injections are being explored as a treatment option to minimise the drawbacks of surgical intervention. Various approaches, including oncolytic viruses and fibronectin-targeting products, have shown promising results. “The incidence rates of cutaneous BCC have doubled over the last 2 decades,” said Dr Antonio Cozzio (Kantonsspital St Gallen, Switzerland) [1]. “Moreover, cutaneous BCC has the highest mutational burden of all human cancers.” The current gold standard therapy for BCC is surgery, which has a recurrence risk of 2–10%. Although staging is not yet widely adopted in clinical practice, it is important because treatment algorithms are closely linked to the disease stage. Dr Cozzio highlighted the recent staging proposed by the European Association of Dermato-Onco...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 5 June 20255 June 2025